Is PGNY a buy according to AI stock analysis?

PGNY AI stock analysis does not label Progyny as an automatic buy because quality and price point in different directions. The business has a defensible niche, minimal debt, and a growing end market, but the stock traded near 39.81x TTM earnings at the cutoff, so a buyer needs confidence in resumed revenue growth and sustained employer adoption.

What is the PGNY AI stock forecast?

The PGNY AI stock forecast uses scenarios, not a guaranteed target. Around the $30.65 cutoff price, the bullish scenario is roughly $36 to $43, the base scenario is roughly $22 to $28, and the bearish scenario is roughly $12 to $18, depending on revenue growth trajectory, competitive dynamics, employer benefit trends, and valuation multiples.

What technical levels matter for PGNY?

The key PGNY technical levels are the $31.36 52-week high resistance zone, the $26.00 to $27.50 near-support zone, and the $21.00 to $22.00 secondary support area. A close below $26 weakens the short-term setup, while a break above $31.36 would confirm the trend continuation.

Can AI predict PGNY stock price?

No, AI cannot reliably predict stock prices. AI can organize SEC filings, market data, valuation math, technical levels, and risk scenarios, but PGNY can still move sharply after earnings, employer client announcements, competitive developments, benefit regulation changes, or shifts in market multiples.

How should I use this PGNY AI trading strategy?

Use this PGNY AI trading strategy as a research checklist, not a personal instruction. Confirm live price, volume, moving averages, earnings timing, position size, stop level, and portfolio risk before making any trade.

What is the biggest risk in Progyny stock analysis?

The biggest risk in Progyny stock analysis is paying a premium multiple for a business whose growth is decelerating. Employer benefit budget cycles, competition from Carrot Fertility and Maven Clinic, customer concentration, and the Q1 2026 revenue decline all matter because the current valuation leaves limited room for disappointment.

Progyny Inc. research snapshot

PGNY AI Stock Analysis

PGNY AI stock analysis currently reads Progyny Inc. as a niche leader in fertility and family-building benefits management with strong free cash flow, minimal debt, and a large addressable market. The analysis is not a certain price prediction. At the July 13, 2026 cutoff, the latest verified close was $30.65, market capitalization was about $2.40 billion, and the main question was whether slowing revenue growth and premium earnings multiples leave enough room for the bull case. This is informational research and not investment advice.

Current price

$30.65

Market cap

$2.40 billion

AI score

62 / 100

Rating

Growing niche leader with slowing momentum and premium valuation

Trend status

Strong uptrend from 52-week low near all-time high zone

Data cutoff (updated weekly)

July 13, 2026

Informational use only. This page is not investment advice.

Research quality check

information Richness: B-level information richness. Progyny has been public since 2019 with moderate analyst coverage. SEC filings are available, but the niche fertility benefits market has less sell-side depth than larger healthcare sectors.
bias Check: The main AI bias risk is over-extrapolating from the strong post-IPO growth trajectory. Progyny faces a tougher comparable period and potential employer benefit budget pressure. This page separates filing-backed data from scenario judgments.
ai Confidence: Medium-high data confidence
investment Certainty: Medium-low. The business model is understandable and the market is growing, but revenue growth is decelerating, the stock trades at a premium multiple, and future performance depends on employer adoption cycles, competitive dynamics, and benefit regulation.

Quick verdict table

Dimension	Conclusion	Confidence
Business quality	Progyny sells fertility and family-building benefits management to US employers. The Smart Cycle bundled model, clinical network, and concierge support create repeat revenue and client stickiness.	Medium-high
Moat	The moat comes from employer switching costs, proprietary Smart Cycle design, selective fertility specialist network, data-driven outcomes, and growing brand recognition in a niche market.	Medium
Management	Founder and CEO Michael Schulman has led the company from startup to public company. The $200M buyback authorization signals confidence, but recent CFO insider selling warrants attention.	Medium
Financial trend	TTM revenue of $1.29 billion and net income of about $67.69 million. Q1 2026 revenue declined 26.4% year-over-year, a sharp deceleration from prior growth rates.	Medium-high
Valuation	The stock traded at about 39.81x TTM earnings and about 11.97x TTM free cash flow at the cutoff. Forward multiples are more reasonable but depend on resumed growth.	Medium
Technical trend	PGNY rallied sharply from its $16.10 52-week low and was testing the $31.36 high zone. Momentum indicators were strong but nearing overbought territory.	Medium-high
Risk level	Key risks are employer benefit budget cycles, competition from Carrot Fertility and Maven Clinic, customer concentration, revenue deceleration, and premium valuation.	Medium-high
AI confidence	Medium-high confidence for the business model, financial filings, and market cap math. Lower confidence for predicting employer adoption pace and competitive outcomes.	Medium-high data confidence
Investment certainty	Medium-low certainty. Progyny has a real business and a growing end market, but the stock price already reflects optimistic expectations for a turnaround in growth.	Medium-low

PGNY AI stock forecast

PGNY AI Stock Forecast Scenarios

The PGNY AI stock forecast uses scenario ranges around the $30.65 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires resumed revenue growth, expanding client wins, and multiple support from the buyback. The base case assumes moderate growth but multiple compression. The bearish case assumes continued growth deceleration or competitive pressure.

Bullish case

$36 to $43

More likely if Progyny returns to double-digit revenue growth, expands Fortune 500 client wins, executes the $200M buyback aggressively, and the market assigns a forward P/E near 28x to 30x.

Base case

$22 to $28

More likely if revenue grows at a mid-single-digit pace, earnings grow modestly, and the market values PGNY near a 20x to 22x forward earnings multiple.

Bearish case

$12 to $18

More likely if revenue growth continues to slow or turns negative, employer benefit budgets tighten, competition intensifies, and the multiple contracts toward 12x to 15x forward earnings.

PGNY AI technical analysis

PGNY AI Technical Analysis

PGNY AI technical analysis starts from the $30.65 July 10 close used for this July 13 static page. The stock rallied strongly from its 52-week low of $16.10 and was trading near the upper end of its range. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.

Level	Value	Why it matters
Current price	$30.65	Latest verified close used for this page as of the July 13, 2026 data cutoff.
Near support	$26.00 to $27.50	Short-term pullback support zone from the recent uptrend.
Secondary support	$21.00 to $22.00	Brokerage-level support representing prior resistance turned support.
Near resistance	$31.00 to $31.36	The 52-week high zone. A breakout above this level would confirm trend continuation.
50-day moving average	About $24.00 to $25.00	Public technical sources showed PGNY trading well above the 50-day moving average.
200-day moving average	About $20.00 to $21.00	The 200-day moving average was well below the current price, confirming the long-term uptrend.
Momentum	RSI near 70, strong uptrend momentum	The RSI was approaching overbought territory after a strong rally from the 52-week low.
Volume	About 990,000 to 1.5 million shares	Volume was moderate. A breakout above $31.36 should be confirmed by above-average participation.
Volatility	Moderate	Beta of about 1.02 suggests PGNY moves roughly in line with the broader market.
Invalidation	Close below $26.00, then $21.00	A close below the near-support zone weakens the short-term setup. A break below the 200-day area would challenge the long-term trend.

PGNY AI trading strategy

PGNY AI Trading Strategy Framework

The PGNY AI trading strategy is a rules-based framework, not personalized advice. It combines filing-backed business evidence, technical confirmation, position sizing, and clear invalidation levels.

Trend-following setup

Look for PGNY to hold above the $26 support zone and break above the $31.36 52-week high with expanding volume before treating the trend as confirmed.

A failed breakout or daily close below $26 should reduce confidence in the setup.

Mean-reversion setup

If PGNY pulls back toward $26 to $27.50 without a thesis break, compare price stabilization with upcoming earnings, employer client growth, and revenue trajectory signals.

Do not average down solely because the business model is defensible. Define maximum loss and review valuation first.

Fundamental monitor

Track next earnings (estimated Aug 6, 2026), quarterly revenue growth, client adds, utilization rates, buyback execution, and competitive announcements from Carrot Fertility and Maven Clinic.

Lower the rating if revenue decline accelerates or forward guidance disappoints while the stock still trades at a premium multiple.

Investment research summary

Four-master Research Compression

Business essence

Progyny helps US employers manage fertility and family-building benefits through a bundled Smart Cycle model, a curated clinical network, and concierge member support, generating recurring per-member fees.

Moat

The moat is employer switching costs, proprietary benefit design, clinic network relationships, outcomes data, and first-mover brand recognition in the fertility benefits niche.

Munger risk inversion

The thesis can fail if employer benefit budgets tighten, clients self-insure and bypass Progyny, competition from well-funded entrants erodes pricing, revenue growth stagnates, or the premium multiple compresses.

Management

Founder-CEO Michael Schulman has guided the company through IPO and rapid growth. The board authorized a $200M buyback in May 2026. Recent CFO insider selling is a monitoring item.

Industry trend

Fertility and family-building benefits are a growing employer priority driven by demographic shifts and competitive talent markets. The US fertility services market continues to expand.

Valuation and margin of safety

At roughly 39.81x TTM earnings and 1.86x TTM revenue, the price leaves limited room for execution missteps. A more attractive entry would require either resumed growth visibility or a lower multiple.

Source-backed data

PGNY Data Table

Every metric below includes a source and last verification date.

Metric	Value	Source	Last verified
PGNY price	$30.65 close on July 10, 2026	Yahoo Finance and MarketBeat quote snapshots	July 13, 2026
Market capitalization	$2.40 billion, verified as $30.65 x 78,332,000 shares	financial_rigor.py market cap verification and MarketBeat	July 13, 2026
TTM revenue	$1.29 billion	Yahoo Finance and MarketBeat	July 13, 2026
TTM net income	$67.69 million	Yahoo Finance key statistics	July 13, 2026
EPS (TTM)	$0.77	Yahoo Finance and MarketBeat	July 13, 2026
Cash and equivalents	$225.11 million	Yahoo Finance key statistics	July 13, 2026
Total debt/equity	6.21%	Yahoo Finance key statistics	July 13, 2026
Free cash flow (levered TTM)	$200.21 million	Yahoo Finance key statistics	July 13, 2026
Forward EPS estimate	$1.19 (current year), $1.37 (next year)	MarketBeat earnings estimates	July 13, 2026
Valuation math	39.81x TTM PE, 5.12x PB, 11.97x P/FCF, 8.35% FCF yield from financial_rigor.py	financial_rigor.py valuation verification	July 13, 2026

Frequently Asked Questions

Read the NVDA AI stock analysis View UNH AI stock forecast Explore AI Stock Picker Generate an AI trading strategy

This PGNY AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 13, 2026 and can be wrong.